Many patients can achieve normal or near-normal glucose levels, but the underlying drivers particularly insulin resistance and excess adiposity [body fat] often persist, says Dr
If you experience minimal appetite reduction or weight change after 8 weeks at therapeutic doses, your genetic profile may favor a different GLP-1 formulation, oral delivery instead of injection, or combination therapy
These capabilities help users monitor the subtle changes that occur during GLP-1 therapy, providing data that can reinforce treatment progress
The first thing we have to understand is what the patients expectations are for weight loss and what these medications can realistically provide, Dr
onceweekly in type 2 diabetes: a population pharmacokinetic analysis
Eli Lilly is expected to present this data to the U.S